nGel Therapeutics is a preclinical-stage regenerative medicine biotech developing innovative cell-based therapy to bring back light to patients who suffer from all forms of retinal degeneration and blindness.
The company is based in Boston and was born at Harvard Medical School. Our lead program, IGT001, is a mutation-agnostic approach to Retinitis Pigmentosa, targeting the restoration of cone metabolism, morphology, and function, leveraging the rescue, repair and regenerative pathways from cell-cell and cell-matrix interaction.
Our preclinical studies have shown best-in-class vision protection, and repair in multiple animal models pointing to potentially transformative vision improvement in patients. No effective treatment is available to rescue and restore vision for most patients affected by Retinitis Pigmentosa. Unlike RP gene therapies, which can target specific genetic mutations IGT001 in mutation-independent.